Initiated Buy X

LEGN Legend Biotech

Redburn Atlantic

$86

Initiated Buy X

LEGN Legend Biotech

Deutsche Bank

$60

Upgrades Sec Perform Sec Outperform X

LEGN Legend Biotech

Scotiabank

$65

Initiated Overweight X

LEGN Legend Biotech

Cantor Fitzgerald

$82

Initiated Outperform X

LEGN Legend Biotech

Raymond James

$86

Initiated Sector Perform X

LEGN Legend Biotech

Scotiabank

Initiated Buy X

LEGN Legend Biotech

Goldman

$90.09

Initiated Mkt Perform X

LEGN Legend Biotech

William Blair

$64

Initiated Buy X

LEGN Legend Biotech

Daiwa Securities

Initiated Buy X

LEGN Legend Biotech

H.C. Wainwright

$66

Initiated Outperform X

LEGN Legend Biotech

RBC Capital Mkts

$73

Initiated Buy X

LEGN Legend Biotech

UBS

$66

Initiated Outperform X

LEGN Legend Biotech

Evercore ISI

Initiated Outperform X

LEGN Legend Biotech

Cowen

Initiated Neutral X

LEGN Legend Biotech

Guggenheim

Initiated Outperform X

LEGN Legend Biotech

BMO Capital Markets

$77

LEGN  Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.